- Home
- BALL vs BBIO Comparison
BALL vs BBIO Comparison
Compare BALL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BALL
- BBIO
- Stock Information
- Founded
- BALL 1880
- BBIO 2015
- Country
- BALL United States
- BBIO United States
- Employees
- BALL N/A
- BBIO N/A
- Industry
- BALL Containers/Packaging
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BALL Industrials
- BBIO Health Care
- Exchange
- BALL Nasdaq
- BBIO Nasdaq
- Market Cap
- BALL 12.8B
- BBIO 12.5B
- IPO Year
- BALL N/A
- BBIO 2019
- Fundamental
- Price
- BALL $49.81
- BBIO $67.77
- Analyst Decision
- BALL Buy
- BBIO Strong Buy
- Analyst Count
- BALL 13
- BBIO 19
- Target Price
- BALL $61.75
- BBIO $74.79
- AVG Volume (30 Days)
- BALL 3.3M
- BBIO 3.0M
- Earning Date
- BALL 11-04-2025
- BBIO 10-29-2025
- Dividend Yield
- BALL 1.60%
- BBIO N/A
- EPS Growth
- BALL N/A
- BBIO N/A
- EPS
- BALL 2.40
- BBIO N/A
- Revenue
- BALL $12,694,000,000.00
- BBIO $353,780,000.00
- Revenue This Year
- BALL $10.84
- BBIO $123.32
- Revenue Next Year
- BALL $3.21
- BBIO $73.46
- P/E Ratio
- BALL $20.81
- BBIO N/A
- Revenue Growth
- BALL 7.41
- BBIO 62.46
- 52 Week Low
- BALL $43.51
- BBIO $22.47
- 52 Week High
- BALL $63.35
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- BALL 59.27
- BBIO 66.07
- Support Level
- BALL $47.15
- BBIO $64.34
- Resistance Level
- BALL $48.53
- BBIO $67.71
- Average True Range (ATR)
- BALL 1.44
- BBIO 2.71
- MACD
- BALL 0.22
- BBIO -0.08
- Stochastic Oscillator
- BALL 90.01
- BBIO 84.09
About BALL Ball Corporation
Ball is the world's largest metal can manufacturer with market share over 30% in its three main regions (North America, Europe, and South America). The company is focused on increasing capacity amid a wave of new developed-market demand, while also investing in faster-growing emerging-market economies. Ball spun-off its glass jar business in 1993 and is now owned by Newell. The company reports three segments—beverage packaging, North and Central America (48% of 2024 revenue), beverage packaging, EMEA (29%), beverage packaging, South America (17%)—and it generated $12 billion in revenue in 2024.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.